8-K: IN8bio Secures $20.1M in Private Placement, Eyes Further $20.1M

IN8bio, Inc. announced a private placement to raise an initial $20.1 million, with an option for an additional $20.1 million contingent on a key clinical milestone and stock performance.

Summary

• IN8bio, Inc. entered into a Securities Purchase Agreement for a private placement with investors on December 18, 2025.
• The initial closing of the private placement is anticipated to occur on or about December 22, 2025.
• At the initial closing, the company will issue an aggregate of 5,127,029 shares of common stock at a purchase price of $1.38 per share.
• In lieu of common stock, pre-funded warrants to purchase up to 9,452,677 warrant shares will be issued at a purchase price of $1.3799 per pre-funded warrant.
• The initial closing is expected to generate aggregate gross proceeds of approximately $20.1 million, before deducting placement agent fees and other private placement expenses.
• A second closing is contingent upon the 'Second Closing Trigger' and could raise an additional $20.1 million in gross proceeds.
• The Second Closing Trigger requires: (i) the presentation of animal model data for the INB-619 product candidate by December 31, 2026 (INB-619 Milestone), AND (ii) the volume weighted average price (VWAP) of common stock being equal to or greater than 200% of the share price ($2.76) over any five consecutive trading days during the 90 trading days following the INB-619 Milestone announcement, OR a waiver of this Price Threshold by majority investors.
• The company may, at its sole discretion, reduce the investors' committed investment amounts for the second closing by an amount equal to any cash proceeds received from licensing, partnership, or other collaboration agreements not attributable to equity issuance.
• Pre-funded warrants have an exercise price of $0.0001 per share, are immediately exercisable, and remain exercisable until fully exercised.
• The company granted each investor the right until December 31, 2026, to participate in a subsequent equity financing up to 200% of their initial and second closing investment amounts.
• A registration rights agreement was also entered into, obligating the company to register for resale the shares and warrant shares no later than 30 days following each closing, with a reasonable best efforts effectiveness deadline of 90 days (if SEC reviews) or 5 business days (if no review).
• If registration deadlines are missed or effectiveness is suspended, the company will pay liquidated damages of 1% of the aggregate amount paid by each investor per 30-day period, capped at 5% of the aggregate purchase price.

Sentiment

Score: 6

Explanation: The capital raise provides essential funding for a clinical-stage biotechnology company, which is a positive for continued operations and development. However, the significant dilution from the issuance of shares and warrants, coupled with the conditional nature of the second tranche, introduces uncertainty and potential downward pressure on the stock. The terms are standard for such financings in the biotech sector.

Positives

• Secured $20.1 million in gross proceeds from the initial closing, providing immediate capital for operations and development.
• Potential to raise an additional $20.1 million upon achieving a key clinical milestone (INB-619 animal model data) and favorable stock performance, linking future funding to scientific progress and market valuation.
• Investors are granted rights to participate in subsequent equity financings up to 200% of their initial and second closing investment amounts until December 31, 2026, indicating continued investor interest.
• The company retains discretion to reduce the second closing amount if it secures non-equity related cash proceeds from licensing or collaboration agreements, offering financial flexibility.

Negatives

• Significant dilution for existing shareholders due to the issuance of 5,127,029 shares and pre-funded warrants for up to 9,452,677 shares in the initial closing, with potential for further dilution in the second closing.
• The second tranche of funding is contingent on both a clinical milestone and a substantial increase in stock price (200% of the share price), introducing uncertainty regarding the full capital raise.
• The company is subject to liquidated damages (1% per 30 days, capped at 5%) if it fails to meet registration statement filing or effectiveness deadlines, or if sales are suspended, which could impact financial performance.

Risks

• Clinical Development Risk: The second tranche of funding is contingent on the INB-619 Milestone (presentation of animal model data), which may not be achieved within the specified timeframe (by December 31, 2026) or may not yield positive results.
• Market Performance Risk: The second tranche is also contingent on the common stock's VWAP reaching 200% of the share price ($2.76) within 90 trading days following the INB-619 Milestone announcement, which is not guaranteed and depends on broader market sentiment and company-specific performance.
• Dilution Risk: The issuance of new shares and pre-funded warrants will dilute the ownership percentage of existing shareholders, potentially impacting per-share metrics.
• Regulatory Risk: Failure to timely file or achieve effectiveness of the registration statement for the resale of securities could result in liquidated damages and potentially impact investor confidence and the company's ability to raise future capital.
• Financing Risk: While the initial tranche is secured, the second tranche is conditional, meaning the company may not receive the full anticipated capital if the specified clinical and market conditions are not met.

Future Outlook

The company anticipates an initial capital infusion of $20.1 million, with a strategic pathway to secure an additional $20.1 million. This second tranche is contingent on achieving the INB-619 animal model data milestone by December 31, 2026, and a significant appreciation in the common stock's volume-weighted average price (200% of the share price) or a waiver from investors. The company also committed to registering the newly issued securities for resale and granted investors rights to participate in future equity financings.

Management Comments

• The company has all requisite corporate power and authority to enter into the Transaction Agreements and to carry out and perform its obligations under the terms of the Transaction Agreements, including the issuance and sale of the Securities and the issuance of the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.
• The company will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
• The company shall use commercially reasonable efforts to maintain the listing and trading of its Common Stock on the Nasdaq Capital Market and, in accordance therewith, will use reasonable best efforts to comply in all material respects with the company’s reporting, filing and other obligations under the rules and regulations of Nasdaq.

Industry Context

This private placement is a common financing strategy for biotechnology companies like IN8bio, which typically require substantial capital to fund preclinical and clinical development of their product candidates. The structured nature of the raise, with a second tranche tied to a clinical milestone (INB-619 animal model data) and stock performance, reflects an attempt to align investor interests with scientific progress and market valuation, a common approach in the high-risk, high-reward biotech sector.

Comparison to Industry Standards

• The two-tranche financing structure, with the second tranche contingent on a clinical milestone and stock performance, is a common mechanism in the biotech industry to de-risk investments and incentivize progress. For example, similar structures have been seen in financings for early-stage oncology companies where funding is released upon IND clearance or phase 1 data readouts.
• The pre-funded warrants with a nominal exercise price ($0.0001) are standard in private placements to institutional investors, allowing them to manage beneficial ownership limitations while still participating fully in the equity upside.
• The registration rights agreement, including liquidated damages for delays, is a typical provision demanded by institutional investors in private placements to ensure liquidity for their unregistered securities, comparable to agreements seen with companies like Moderna or BioNTech in their earlier financing rounds.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the issuance of new shares and pre-funded warrants. However, the capital raise provides necessary funding for the company's operations and clinical programs, which could ultimately benefit long-term shareholder value if successful.
• Investors (Purchasers): Acquire common stock and pre-funded warrants at a set price, with potential for additional investment. They also gain registration rights for liquidity and participation rights in future financings.
• Employees: Continued funding supports ongoing research and development, potentially safeguarding jobs and advancing product candidates.
• Creditors: Improved financial liquidity from the capital raise may reduce credit risk.

Next Steps

• Initial Closing of the private placement on or about December 22, 2025.
• Company to file a registration statement for resale of initial closing securities within 30 days of the Initial Closing Date.
• Company to use reasonable best efforts to achieve effectiveness of the initial registration statement within 90 days (if SEC reviews) or 5 business days (if no review).
• Company to present animal model data for INB-619 by December 31, 2026, to potentially trigger the Second Closing.
• If Second Closing Trigger conditions are met, company to provide Second Closing Notice within 2 trading days.
• Second Closing to occur within 5 business days of Second Closing Notice Date.
• Company to file a registration statement for resale of second closing securities within 30 days of the Second Closing Date.
• Company to use reasonable best efforts to achieve effectiveness of the second registration statement within 90 days (if SEC reviews) or 5 business days (if no review).
• Investors have the right to participate in subsequent equity financings until December 31, 2026.

Key Dates

Keywords

IN8bio, INAB, private placement, common stock, pre-funded warrants, capital raise, biotechnology, clinical milestone, INB-619, SEC filing, equity financing, dilution, registration rights